lyophilized powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-27. Numbers and descriptions here follow the published literature rather than marketing material.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
=== Occurrence of other cyclopropane fatty acids === The biosynthesis and occurrence of lactobacillic acid is closely linked to dihydrosterculic acid (compare sterculic acid), which is also a saturated fatty acid with the molecular formula C19H36O2, which contains a cyclopropane ring. Here, however, the ring is located at positions 9 and 10 of the carbon chain, which is why it is also referred to as cis-9,10-methylenoctadecanoic acid. Dihydrosterculic acid is also found in the lipids of many bacterial genera, but has also been found in eukaryotes, for example in protozoa from the Trypanosomatida group, here in the genera Crithidia, Leishmania, Leptomonas, Herpetomonas and Phytomonas. According to a study published in 2014, lactobacillic acid and dihydrosterculic acid are also found in cow's milk in very small quantities (< 0.1% of total fatty acids), but not in the milk of goats or sheep.
Outback Steakhouse is an American chain of Australian-themed casual dining restaurants, serving American cuisine, based in Tampa, Florida. The chain has over 1,000 locations in 23 countries throughout North America, South America, Asia, and Australia. It was founded on March 15, 1988, with its first location in Tampa by Bob Basham, Chris T. Sullivan, Trudy Cooper, and Tim Gannon. It was owned and operated in the United States by OSI Restaurant Partners until it was acquired by Bloomin' Brands, and by other franchise and venture agreements internationally.
== Clinical significance == The multiple roles of moonlighting proteins complicates the determination of phenotype from genotype, hampering the study of inherited metabolic disorders. The complex phenotypes of several disorders are suspected to be caused by the involvement of moonlighting proteins. The protein GAPDH has at least 11 documented functions, one of which includes apoptosis. Excessive apoptosis is involved in many neurodegenerative diseases, such as Huntington's, Alzheimer's, and Parkinson's as well as in brain ischemia. In one case, GAPDH was found in the degenerated neurons of individuals who had Alzheimer's disease. Although there is insufficient evidence for definite conclusions, there are well documented examples of moonlighting proteins that play a role in disease. One such disease is tuberculosis. One moonlighting protein in M. tuberculosis has a function which counteracts the effects of antibiotics. Specifically, the bacterium gains antibiotic resistance against ciprofloxacin from overexpression of glutamate racemase in vivo. GAPDH localized to the surface of pathogenic mycobacteria has been shown to capture and traffic the mammalian iron carrier protein transferrin into cells resulting in iron acquisition by the pathogen.
Sources: en.wikipedia.org
=== Texas === Low-income minority women were more dependent on sterilization than other groups. In a study conducted in El Paso, Texas, groups of women were asked why they would choose sterilization; many of the top reasons included: not wanting any more children, their current age and health, plans of working or attending school or inability to afford another child.
==== Cost ==== The price of using either type of support is a key determining factor in using agarose or magnetic beads for immunoprecipitation applications. A typical first-glance calculation on the cost of magnetic beads compared to sepharose beads may make the sepharose beads appear less expensive. But magnetic beads may be competitively priced compared to agarose for analytical-scale immunoprecipitations depending on the IP method used and the volume of beads required per IP reaction. Using the traditional batch method of immunoprecipitation as listed below, where all components are added to a tube during the IP reaction, the physical handling characteristics of agarose beads necessitate a minimum quantity of beads for each IP experiment (typically in the range of 25 to 50 μl beads per IP). This is because sepharose beads must be concentrated at the bottom of the tube by centrifugation and the supernatant removed after each incubation, wash, etc. This imposes absolute physical limitations on the process, as pellets of agarose beads less than 25 to 50 μl are difficult if not impossible to visually identify at the bottom of the tube. With magnetic beads, there is no minimum quantity of beads required due to magnetic handling, and therefore, depending on the target antigen and IP antibody, it is possible to use considerably less magnetic beads. Conversely, spin columns may be employed instead of normal microfuge tubes to significantly reduce the amount of agarose beads required per reaction.
A mixer-settler consists of a mixing stage that often forms a suspension of two immiscible liquids followed by a settling stage that allows the liquids to separate into two layers by gravity. Mixer-settlers are typically used when a process requires longer residence times and when the solutions are easily separated by gravity. In a multistage countercurrent process, multiple mixer-settlers are installed in series with the settled output of one stage being fed to subsequent stages for further separation.
== ISO 4500 - ISO 4999 == ISO 4548 Methods of test for full-flow lubricating oil filters for internal combustion engines ISO 4548-7:2012 Part 7: Vibration fatigue test ISO 4551:1987 Ferroalloys – Sampling and sieve analysis ISO 4552 Ferroalloys – Sampling and sample preparation for chemical analysis ISO 4552-1:1987 Part 1: Ferrochromium, ferrosilicochromium, ferrosilicon, ferrosilicomanganese, ferromanganese ISO 4552-2:1987 Part 2: Ferrotitanium, ferromolybdenum, ferrotungsten, ferroniobium, ferrovanadium ISO 4570 Tyre valve threads ISO 4578 Adhesives — Determination of peel resistance of high-strength adhesive bonds — Floating-roller method ISO 4582 Plastics — Determination of changes in colour and variations in properties after exposure to daylight under glass, natural weathering or laboratory light sources ISO 4587 Adhesives — Determination of tensile lap-shear strength of rigid-to-rigid bonded assemblies ISO 4618:2014 Paints and varnishes – Terms and definitions ISO 4628 Paints and varnishes – Evaluation of degradation of coatings – Designation of quantity and size of defects, and of intensity of uniform changes in appearance ISO 4628-1 General introduction and designation system ISO 4628-2 Assessment of degree of blistering ISO 4628-3 Assessment of degree of rusting ISO 4628-4 Assessment of degree of cracking ISO 4628-5 Assessment of degree of flaking ISO 4628-6 Assessment of degree of chalking by tape method ISO 4628-7 Assessment of degree of chalking by velvet method ISO 4628-8 Assessment of degree of delamination and corrosion around a scribe ISO 4628-10 Assessment of degree of filiform corrosion ISO 4648:1991 Rubber, vulcanized or thermoplastic — Determination of dimensions of test pieces and products for test purposes [Withdrawn: replaced with ISO 23529] ISO 4661 Rubber, vulcanized — Preparation of samples and test pieces ISO 4661-1:1993 Rubber, vulcanized or thermoplastic — Preparation of samples and test pieces — Part 1: Physical tests [Withdrawn: replaced with ISO 23529] ISO 4661-2:2018 Rubber, vulcanized — Preparation of samples and test pieces — Part 2: Chemical tests ISO 4683 Raw sheep skins ISO 4683-1:1998 Part 1: Descriptions of defects ISO 4720:2009 Essential oils – Nomenclature ISO 4730:2017 Essential oil of Melaleuca, terpinen-4-ol type (Tea Tree oil) ISO 4786:1977 Enclosed-scale adjustable-range thermometers [Withdrawn without replacement] ISO 4787:2010 Laboratory glassware – Volumetric instruments – Methods for testing of capacity and for use ISO 4788:2005 Laboratory glassware – Graduated measuring cylinders ISO 4791 Laboratory apparatus – Vocabulary relating to apparatus made essentially from glass, porcelain or vitreous silica ISO 4791-1:1985 Part 1: Names for items of apparatus ISO 4795:1996 Glass for thermometer bulbs ISO 4801:1979 Glass alcoholometers and alcohol hydrometers not incorporating a thermometer ISO 4805:1982 Laboratory glassware – Thermo-alcoholometers and alcohol-thermohydrometers ISO 4824:1993 Dentistry — Ceramic denture teeth [Withdrawn: replaced with ISO 22112] ISO 4831:2006 Microbiology of food and animal feeding stuffs – Horizontal method for the detection and enumeration of coliforms – Most probable number technique ISO 4832:2006 Microbiology of food and animal feeding stuffs – Horizontal method for the enumeration of coliforms – Colony-count technique ISO 4833 Microbiology of the food chain – Horizontal method for the enumeration of microorganisms ISO 4833-1:2013 Part 1: Colony count at 30 degrees C by the pour plate technique ISO 4833-2:2013 Part 2: Colony count at 30 degrees C by the surface plating technique ISO 4848:1980 Concrete — Determination of air content of freshly mixed concrete — Pressure method [Withdrawn: replaced with ISO 1920-2] ISO 4858:1982 Wood — Determination of volumetric shrinkage [Withdrawn: replaced with ISO 13061-14] ISO 4859:1982 Wood — Determination of radial and tangential swelling [Withdrawn: replaced with ISO 13061-15] ISO 4860:1982 Wood — Determination of volumetric swelling [Withdrawn: replaced with ISO 13061-16] ISO 4866:2010 Mechanical vibration and shock – Vibration of fixed structures – Guidelines for the measurement of vibrations and evaluation of their effects on structures ISO 4871:1996 Acoustics – Declaration and verification of noise emission values of machinery and equipment ISO/IEC 4873:1991 Information technology – ISO 8-bit code for information interchange – Structure and rules for implementation ISO 4875 Metal-cutting band saw blades ISO 4875-1:2006 Part 1: Vocabulary ISO 4880:1997 Burning behaviour of textiles and textile products – Vocabulary ISO 4882:1979 Office machines and data processing equipment – Line spacings and character spacings ISO 4885:2017 Ferrous materials – Heat treatments – Vocabulary ISO 4892 Plastics – Methods of exposure to laboratory light sources ISO 4902:1989 Information technology – Data communication – 37-pole DTE/DCE interface connector and contact number assignments ISO 4903:1989 Information technology – Data communication – 15-pole DTE/DCE interface connector and contact number assignments ISO/IEC 4909:2006 Identification cards – Financial transaction cards – Magnetic stripe data content for track 3 ISO 4921:2000 Knitting – Basic concepts – Vocabulary ISO/IEC 4922-1 Information security — Secure multiparty computation ISO/IEC 4922-1:2023 Part 1: General ISO 4977 Double cold-reduced electrolytic tinplate ISO 4977-1:1984 Part 1: Sheet [Withdrawn: replaced with ISO 11949] ISO 4977-2:1984 Part 2: Coil for subsequent cutting into sheets [Withdrawn: replaced with ISO 11949]
Sources: en.wikipedia.org
It has been suggested that the same may have been true for clomipramine and other TCAs. Nonetheless, there is little doubt that many may, indeed, benefit from much higher doses. 250 mg/d, as mentioned elsewhere, is the typical maximum recommended dose but some people may need as much as 300 mg/d or more to benefit from all clomipramine has to offer beyond its potent SNRI capacity alone.
An opioidergic agent (or drug) is a chemical which directly or indirectly modulate the function of opioid receptors. Opioidergics comprise opioids, as well as allosteric modulators and enzyme affecting agents like enkephalinase inhibitors.
== List of anorectics == Numerous pharmaceutical compounds are marketed as appetite suppressants. The following drugs are listed as "centrally-acting antiobesity preparations" in the Anatomical Therapeutic Chemical Classification System:
Baritosis, a benign pneumoconiosis is associated with inhalation of dust containing barium sulfate or barium carbonate; the effects are reversible. Silver poisoning, like lithium poisoning, arises from misapplication of medications. A dramatic symptom of "argyria" is that the skin turns blue or bluish-grey. Thallium poisoning has been observed on several occasions, and it is well known that thallium compounds are highly toxic. Nonetheless, incidents of thallium poisoning are few. Tin poisoning from tin metal, its oxides, and its salts are "almost unknown"; on the other hand certain organotin compounds are almost as toxic as cyanide. Such organotin compounds were once widely used as anti-fouling agents.
==== Oral activity and hepatotoxicity ==== Non-17α-alkylated testosterone derivatives such as testosterone itself, DHT, and nandrolone all have poor oral bioavailability due to extensive first-pass hepatic metabolism and hence are not orally active. A notable exception to this are AAS that are androgen precursors or prohormones, including dehydroepiandrosterone (DHEA), androstenediol, androstenedione, boldione (androstadienedione), bolandiol (norandrostenediol), bolandione (norandrostenedione), dienedione, mentabolan (MENT dione, trestione), and methoxydienone (methoxygonadiene) (although these are relatively weak AAS). AAS that are not orally active are used almost exclusively in the form of esters administered by intramuscular injection, which act as depots and are long-acting prodrugs. Examples include testosterone, as testosterone cypionate, testosterone enanthate, and testosterone propionate, and nandrolone, as nandrolone phenylpropionate and nandrolone decanoate, among many others (see here for a full list of testosterone and nandrolone esters). An exception is the long-chain ester testosterone undecanoate, which is orally active, albeit with only low oral bioavailability (approximately 3%). In contrast to most other AAS, 17α-alkylated testosterone derivatives show resistance to metabolism due to steric hindrance and are orally active, though they may be esterified and administered via intramuscular injection as well.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.